Dow Chemical is to sell its Styron unit to Bain Capital, two sources familiar with the matter said on Tuesday. Dow, the No. 1 U.S. chemicals company, put Styron up for sale in July and said at the time the unit could fetch $1 billion to $2 billion. It hopes to sell the unit, which makes polystyrene, rubber and latex, by the first quarter of 2010.
The deal is to be worth more than $1.5 billion, one of the sources said.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
Asahi Kasei Life Science, a division of global manufacturer Asahi Kasei, announced plans to construct a new spinning plant for its Planova virus removal filters in Nobeoka City, Miyazaki, Japan.
